Get started
Author

М. М. Панкрашкина

Observed names: M M PANKRASHKINA, M. M. Pankrashkina, M. M. Pankraskina, M. Pankrashkina, Maria M. Pankrashkina, Maria Pankrashkina, М.М. Панкрашкина, Панкрашкина М.М., Панкрашкина Мария Михайловна
Institution: Botkin Hospital
Observed institutions: Imperial College Healthcare NHS Trust, Hammersmith Hospital, Ministry of Health of the Russian Federation, Botkin Hospital, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Scientific Research Institute of Healthcare Organization and Medical Management, City Clinical Hospital, Hopital Universitaire Habib Bourguiba
ORCID: 0000-0002-5658-9729
Observed ORCID: 0000-0002-5658-9729
OpenAlex ID: A5025597615
Evolution of platelet function in adult patients with chronic immune thrombocytopenia on romiplostim treatment
2019 · Anastasia A. Ignatova, Irina A. Demina, et al. · British Journal of Haematology · 17
PDF
Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice
2018 · V V PTUSHKIN, O Yu VINOGRADOVA, et al. · Terapevticheskii arkhiv · 10
PDF
Development and Validation Results of the Russian MPN10 Form for Symptom Assessment in Patients with Myeloproliferative Neoplasms Compliant with International Recommendations
2020 · T. I. Ionova, O.Yu. Vinogradova, et al. · Clinical oncohematology · 7
PDF
Targeted Therapy of Myelofibrosis
2017 · Ol’ga Yur’evna Vinogradova, V. A. Shuvaev, et al. · Clinical oncohematology · 5
PDF
Molecular markers as possible efficacy predictors of targeted therapy for myelofibrosis: single-center study
2023 · O. Yu. Vinogradova, D. I. Shikhbabaeva, et al. · Oncohematology · 4
PDF
Качество жизни и спектр симптомов у больных миелофиброзом на фоне терапии: данные клинической практики
2019 · Tatyana Ionova, Л. В. Анчукова, et al. · Гематология и трансфузиология · 4
Primary Immune Thrombocytopenia and Thrombopoietin Receptor Agonists: Feasibilities of Treatment Discontinuation upon Achieving Stable Complete Platelet Response
2023 · O. Yu. Vinogradova, M. M. Pankrashkina, et al. · Clinical oncohematology · 3
PDF
Quality of Life Changes in Patients with Chronic Immune Thrombocytopenia in the Process of Romiplostim Therapy, its Efficacy and Safety in the Real-World Setting: Results of a Multi-Center Observational Study
2023 · T. I. Ionova, O. Yu. Vinogradova, et al. · Clinical oncohematology · 3
PDF
Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia
2017 · Evgenii Aleksandrovich Nikitin, E. A. Dmitrieva, et al. · Clinical oncohematology · 3
Characteristics of regional epidemiological indicators of chronic myeloproliferative neoplasms
2025 · O. Yu. Vinogradova, A. L. Neverova, et al. · Oncohematology · 2
PDF
Possibilities of targeted therapy for myelofibrosis: Moscow experience
2022 · O. Yu. Vinogradova, M. M. Pankrashkina, et al. · Oncohematology · 2
PDF
Treatment opportunities for refractory immune thrombocytopenia
2024 · M. M. Pankraskina, O. Yu. Vinogradova, et al. · MD-Onco · 1
Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
2024 · O. Yu. Vinogradova, M. M. Pankraskina, et al. · Oncohematology · 1
PDF
Long-term dynamics of epidemiological characteristics of some chronic leukemia and lymphoma in Moscow before, during and after the pandemic of the new coronavirus infection COVID-19. Epidemiologic study
2024 · Olga Yu. Vinogradova, Mikhail V. Chernikov, et al. · Journal of Modern Oncology · 1
PDF
Targeted therapy for advanced forms of systemic mastocytosis in real clinical practice
2023 · D. I. Shikhbabaeva, O. Yu. Vinogradova, et al. · Oncohematology · 1
PDF
Clinical Experience and Perspectives of Bosutinib Use in Patients with Chronic Myeloid Leukemia
2018 · V. A. Shuvaev, Ol’ga Yur’evna Vinogradova, et al. · Clinical oncohematology · 1
PDF
Genetic landscape of patients at diagnosis of chronic myeloid leukemia in the chronic phase: association with targeted therapy efficacy
2026 · O. Yu. Vinogradova, A. L. Neverova, et al. · Oncohematology
Применение агонистов рецептора тромбопоэтина при резистентных формах иммунной тромбоцитопении
2026 · М.М. Панкрашкина, О.Ю. Виноградова, et al. · Тромбоз гемостаз и реология
Гипотиреоз В Течение Первого Года После Лучевой Терапии На Шейно-надключичную Область
2026 · И.И. Амергулов, М.Г. Павлова, et al. · Axis of endocrinology
Состояние Щитовидной Железы До И В Течение Первых Недель После Лучевой Терапии На Шейно-надключичную Область
2026 · И.И. Амергулов, М.Г. Павлова, et al. · Axis of endocrinology
Biosimilar of the monoclonal antibody immunoglobulin G1κ daratumumab in treatment regimens for multiple myeloma patients
2026 · M. M. Pankrashkina, A. L. Neverova, et al. · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology
PDF
Genetic features of indolent and advanced forms of systemic mastocytosis
2025 · D. I. Shikhbabaeva, O. Yu. Vinogradova, et al. · Oncohematology
PDF
Primary and secondary myelofibrosis: ophthalmological manifestations at onset and during therapy
2025 · O. Yu. Vinogradova, L. B. Egoryan, et al. · Oncohematology
Results of long-term treatment with thrombopoietin receptor agonists of resistant primary immune thrombocytopenia
2024 · O. Yu. Vinogradova, M. M. Pankrashkina, et al. · Oncohematology
PDF
Diagnosis and Treatment of Primary Immune Thrombocytopenia. Literature Review
2024 · Л.А. Муха, М.М. Панкрашкина, et al. · Гематология Трансфузиология Восточная Европа
PDF
Works count: 50
Citation count: 65
H-index: 4
I10-index: 2
Year
Topic
Type